1. Home
  2. CRT vs LUNG Comparison

CRT vs LUNG Comparison

Compare CRT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cross Timbers Royalty Trust

CRT

Cross Timbers Royalty Trust

HOLD

Current Price

$10.29

Market Cap

59.8M

Sector

Energy

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.41

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRT
LUNG
Founded
1991
1995
Country
United States
United States
Employees
2
N/A
Industry
Oil & Gas Production
Industrial Specialties
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.8M
57.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CRT
LUNG
Price
$10.29
$1.41
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
55.4K
388.1K
Earning Date
04-14-2026
04-29-2026
Dividend Yield
6.46%
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
$11.55
N/A
Revenue Growth
N/A
8.01
52 Week Low
$7.07
$1.13
52 Week High
$11.10
$5.46

Technical Indicators

Market Signals
Indicator
CRT
LUNG
Relative Strength Index (RSI) 55.27 49.46
Support Level $9.33 $1.36
Resistance Level $11.10 $1.93
Average True Range (ATR) 0.50 0.10
MACD -0.05 0.02
Stochastic Oscillator 59.48 72.35

Price Performance

Historical Comparison
CRT
LUNG

About CRT Cross Timbers Royalty Trust

Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: